<DOC>
	<DOCNO>NCT00047632</DOCNO>
	<brief_summary>The purpose study determine : 1 ) treatment interferon gamma-1b plus standard chemotherapy ( carboplatin paclitaxel ) increase overall survival patient advance ovarian primary peritoneal carcinoma compare chemotherapy alone ; 2 ) effective interferon gamma-1b plus standard chemotherapy prevent progression return cancer ; 3 ) effect quality life ; 4 ) safety interferon gamma-1b combine standard chemotherapy compare chemotherapy alone .</brief_summary>
	<brief_title>Safety Efficacy Interferon Gamma-1b Plus Chemotherapy Ovarian Peritoneal Cancer</brief_title>
	<detailed_description>Approximately 800 patient receive either chemotherapy alone chemotherapy plus Interferon gamma-1b . Chemotherapy paclitaxel ( 175 mg/m2 3 hour ) follow carboplatin ( AUC 6 ) every 3 week . Only patient treatment arm receive interferon dos . Interferon gamma-1b 100 mg administer subcutaneously 3 time per week ( every day ; 3 dos 7-day period ) continuously patient treat carboplatin / paclitaxel ( include 3 week follow last dose chemotherapy ) . A total 6 cycle chemotherapy give unless disease progression lime toxicity occur patient refuse treatment . Each patient receive total 54 dos period 18 week . Each patient 's participation 3-8 year duration .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm epithelial ovarian primary peritoneal carcinoma , FIGO Stage III IV disease . Patients either optimal ( &lt; = 1 cm residual disease ) suboptimal residual disease follow initial surgery eligible . Unstained slide primary tumor , primary tumor block , cytological preparation must available review . Patients follow histologic epithelial cell type eligible : serous adenocarcinoma , endometrioid adenocarcinoma , mucinous adenocarcinoma , undifferentiated carcinoma , clear cell adenocarcinoma , mixed epithelial carcinoma , transitional cell carcinoma , malignant Brenner 's Tumor , adenocarcinoma N.O.S . &lt; = 12 week initial surgery adequate recovery surgery . Candidate firstline chemotherapy Adequate bone marrow function ( ANC &gt; = 1,500/mL ; platelet &gt; = 100,000/mL ; hemoglobin &gt; = 10 gm/dL ) Adequate hepatic function ( AST , ALT , alkaline phosphatase &lt; = 2.5 x upper limit normal ; bilirubin &lt; = 1.5 x upper limit normal ) . Adequate renal function ( creatinine &lt; = 1.5 x upper limit normal ) . Adequate neurologic function ( sensory motor neuropathy &lt; = NCI CTC Grade 1 ) . Negative urine pregnancy test woman childbearing potential ( within 14 day initiation first chemotherapy cycle ) . Zubrod / ECOG / GOG performance score 02 . Able give inform consent . Exclusion criterion : Epithelial ovarian tumor low malignant potential ( borderline carcinoma ) . If diagnosis base cytology alone [ ( e.g. , fine needle aspiration ( FNA ) ] , slide must available , confound carcinoma nonovarian mucinous , colorectal , Fallopian tube , adenocarcinomas nonovarian origin must rule . Prior therapy ovarian primary peritoneal carcinoma primary surgical debulking . Patients therapy ovarian primary peritoneal carcinoma addition protocol therapy plan . Prior biological response modifier ( BRM ) reason within previous 5 year . Prior malignancy within previous 5 year basal cell squamous cell carcinoma situ carcinoma cervix . Patients malignancy &gt; 5 year previously may eligible trial receive antineoplastic treatment within previous 5 year dif without evidence disease previous 5 year . Uncontrolled infection . Pregnant nursing woman exclude . Women childbearing potential must agree use chemical barrier contraceptive dose portion study . Any illness condition opinion investigator may affect safety treatment evaluation study 's endpoint .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>ovarian</keyword>
	<keyword>carcinoma</keyword>
	<keyword>peritoneal</keyword>
	<keyword>cancer</keyword>
	<keyword>ovary</keyword>
	<keyword>interferon gamma</keyword>
</DOC>